Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious Pathogens

Inclusion Criteria:

* Age 18 and older, male or female
* Patient is able to understand and fully participate in the activities of the study and the consent in accordance with federal regulations.
* Patients who were involved in the previous study with defined post-COVID neurologic symptoms.
* New patients who have been diagnosed with post-COVID neurologic symptoms.

Exclusion Criteria:

* Receiving any form of C1-INH therapy, either acute or prophylactic treatment
* History or suspicion of allergy to rabbits
* Neurological conditions related to injury
* Neuropathy related to diabetes
* Abnormal kidney or liver enzymes
* History of thrombotic stroke
* Participants who are pregnant or lactating
* Largely incapacitated or bed-ridden
* Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study or have discontinued within 30 days of study entry from any other clinical study involving and investigational product.